Fungal infections cause more than 1.5 million deaths annually. With an increase in immune-
deficient susceptible populations and the emergence of antifungal drug resistance, there is …

A poorly exploited paradigm in the antimicrobial therapy field is to target virulence traits for
drug development. In contrast to target-focused approaches, antivirulence phenotypic …

Each year, fungi cause more than 1.5 billion infections worldwide and have a devastating
impact on human health, particularly in immunocompromised individuals or patients in …

To cause disease, a microbial pathogen must adapt to the challenges of its host
environment. The leading fungal pathogen Candida albicans colonizes nutrient-poor bodily …

Candida albicans is an opportunistic fungal pathogen and most prevalent species among
clinical outbreaks. It causes a range of infections, including from mild mucosal infections to …

Methods: To address the pressing need for new antifungals, we have performed a high-
content screen of 20,000 small molecules in a chemical library (NOVACore) to identify …

Fungal pathogens are increasingly appreciated as a significant infectious disease
challenge. Compared to bacteria, fungal cells are more closely related to human cells, and …

Invasive fungal infections are accompanied by high mortality rates that range up to 90%. At
present, only three different compound classes are available for use in the clinic, and these …

Candida albicans biofilms are a complex multilayer community of cells that are resistant to
almost all classes of antifungal drugs. The bottommost layers of biofilms experience nutrient …

Aims Indole is a signalling molecule, produced by a number of Gram‐positive and Gram‐
negative bacteria both in nature as well as clinical environments. Here, we explored the …